Suter W, Ahiabor R, Blanco B, Locher F, Mantovani F, Robinson M, Sreenan G, Staedtler F, Swingler T, Vignutelli A, Perentes E
Sandoz Pharma Ltd., Basel, Switzerland.
Environ Mol Mutagen. 1996;28(4):354-62. doi: 10.1002/(SICI)1098-2280(1996)28:4<354::AID-EM9>3.0.CO;2-B.
Three genotoxic mouse carcinogens, 4-chloro-o-phenylenediamine (4-C-o-PDA), 2-nitro-p-phenylenediamine (2-N-p-PDA), and 2,4-diaminotoluene (2,4-DAT), were tested in the Big Blue transgenic mouse mutation assay. Each experiment consisted of a vehicle control group with ten Big Blue C57BL/6 mice, five of either sex, and an equally sized group treated with a high dose of the test chemical. In addition, four animals were treated with the vehicle and six animals with the test compound for the measurement of bromodeoxyuridine (BrdU) incorporation to determine cellular proliferation. Prior to the mutagenicity experiments, the maximally tolerated dose of each compound was determined using nontransgenic C57BL/6 mice. Based on these results the doses used in the main study were 200 mg/kg/day for 4-C-o-PDA, 150 mg/kg/ day for 2-N-p-PDA, and 80 mg/kg/day for 2,4-DAT. Animals were treated for 10 days over a 2 week period and were killed 10 days after the ast treatment. In an additional experiment with 2,4-DAT, animals were killed 28 days after treatment. Since all three chemicals are liver carcinogens in the mouse, the DNA of the liver was analyzed using the standard procedures for the Big Blue assay. Hepatocyte proliferation was assessed by immunohistochemical detection of proliferating cell nuclear antigen (PCNA) and, in some studies, by measuring BrdU incorporation. 4-C-o-PDA and 2-N-p-PDA did not induce an increase in PCNA expression when measured 10 days after the last treatment. There was no increase in BrdU incorporation immediately after treatment with 4-C-o-PDA or with 2,4-DAT. However, 10 days after the last treatment with 2,4-DAT, a strong mitogenic effect was found with both techniques, i.e., in the PCNA and BrdU assays. 4-C-o-PDA, a liver carcinogen in both genders of mice, induced a small, statistically significant increase of the mutant frequencies in females. No increase was found in males. 2-N-p-PDA, which has been reported to induce liver tumors only in females, was found positive in males and was clearly negative in females. 2,4-DAT, a liver carcinogen in female mice, was positive in females and negative in males when the animals were killed 10 days after the last treatment. After an expression time of 28 days, 2,4-DAT induced a statistically significant increase in both sexes. The effect in females was marginally stronger than after 10 days' expression time and almost identical to the effect observed in males under these test conditions. In conclusion, the experiments showed that the Big Blue assay detects the genotoxicity of the three carcinogenic monocyclic aromatic amines tested. However, it seems that the sex specificity of the carcinogenic effects of these compounds is not reflected by the mutagenicity data in Big Blue mice.
在大蓝转基因小鼠突变试验中对三种具有基因毒性的小鼠致癌物进行了测试,它们分别是4-氯邻苯二胺(4-C-o-PDA)、2-硝基对苯二胺(2-N-p-PDA)和2,4-二氨基甲苯(2,4-DAT)。每个实验都包括一个载体对照组,该组有十只大蓝C57BL/6小鼠,雌雄各五只,以及一个同样大小的用高剂量受试化学品处理的组。此外,用载体处理四只动物,用受试化合物处理六只动物,以测量溴脱氧尿苷(BrdU)掺入情况来确定细胞增殖。在进行致突变性实验之前,使用非转基因C57BL/6小鼠确定了每种化合物的最大耐受剂量。基于这些结果,在主要研究中使用的剂量分别为:4-C-o-PDA为200mg/kg/天,2-N-p-PDA为150mg/kg/天,2,4-DAT为80mg/kg/天。动物在两周内接受10天的处理,并在最后一次处理后10天处死。在一项关于2,4-DAT的额外实验中,动物在处理后28天处死。由于所有这三种化学品在小鼠中都是肝脏致癌物,因此使用大蓝试验的标准程序分析肝脏的DNA。通过免疫组织化学检测增殖细胞核抗原(PCNA)来评估肝细胞增殖,在一些研究中,也通过测量BrdU掺入来评估。在最后一次处理后10天测量时,4-C-o-PDA和2-N-p-PDA并未诱导PCNA表达增加。在用4-C-o-PDA或2,4-DAT处理后,BrdU掺入立即没有增加。然而,在最后一次用2,4-DAT处理后10天,在PCNA和BrdU试验这两种技术中都发现了强烈的促有丝分裂作用。4-C-o-PDA是雌雄小鼠的肝脏致癌物,在雌性小鼠中诱导突变频率有小幅的、具有统计学意义的增加。在雄性小鼠中未发现增加。2-N-p-PDA据报道仅在雌性小鼠中诱导肝脏肿瘤,在雄性小鼠中呈阳性,在雌性小鼠中明显呈阴性。2,4-DAT是雌性小鼠的肝脏致癌物,在最后一次处理后10天处死动物时,在雌性小鼠中呈阳性,在雄性小鼠中呈阴性。在表达28天后,2,4-DAT在两性中均诱导出具有统计学意义的增加。雌性小鼠中的效应略强于表达10天后的效应,并且几乎与在这些测试条件下在雄性小鼠中观察到的效应相同。总之,实验表明大蓝试验检测到了所测试的三种致癌单环芳香胺的基因毒性。然而,这些化合物致癌效应的性别特异性似乎并未在大蓝小鼠的致突变性数据中得到体现。